SCHEMBL5415326

SCHEMBL5415326

CC(C)Cn1c(=O)n(C)c(=O)c2c(-c3cccc(C(=O)O)c3)n(Cc3csc4ccccc34)nc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CMA1 P23946 1/20 0.38
KDM4E B2RXH2 2/20 0.37
PDE1A P54750 2/20 0.37
PDE1B Q01064 2/20 0.37
PDE1C Q14123 2/20 0.37
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ADORA2B P29275 1/20 0.35
SLC16A1 P53985 2/20 0.35
CYP2C9 P11712 1/20 0.35
MAPKAPK2 P49137 1/20 0.35
CAMK2B Q13554 1/20 0.35
HIPK4 Q8NE63 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5411081 0.90 SMN1; SMN2 (0.41) DPP4KMT2AMEN1CMA1PDE1A
SCHEMBL5407645 0.87 SLC16A1 (0.47) DPP4KMT2AMEN1KDM4EPDE1A
SCHEMBL5400117 0.87 CMA1 (0.37) KMT2AMEN1CMA1PDE1APDE1B
SCHEMBL5398859 0.86 SLC16A1 (0.45) SLC16A1CYP2C9
SCHEMBL5407655 0.86 SLC16A1 (0.37) KMT2AMEN1CMA1PDE1APDE1B
SCHEMBL5395357 0.85 PDE5A (0.39) CMA1PDE1APDE1BPDE1CALDH1A1
SCHEMBL5407705 0.85 DPP4 (0.40) DPP4KMT2AMEN1KDM4EPDE1A
SCHEMBL5405716 0.83 TP53 (0.44) DPP4CMA1PDE1APDE1BPDE1C
SCHEMBL5409632 0.83 PDE1A (0.38) CMA1PDE1APDE1BPDE1CALDH1A1
SCHEMBL5407969 0.83 SLC22A12 (0.46) DPP4KMT2AMEN1CMA1PDE1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC DPP4 266/4885KMT2A 3837/4885MEN1 4216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.